Clinical trials: SARS-COV 2
Cystic Fibrosis, Sickle Cell Disease
Exercise in Child Health
This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) UCI (lead site with its affiliate CHOC), 2) Northwestern University…
- Conditions
- Cystic Fibrosis, Sickle Cell Disease, SARS CoV 2 Infection
- Trial name
- Project REACH (NCT05359991)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
Coronavirus Infection, Orthopedic Disorder
Retrospective Case Series of COVID19+ Patients Undergoing Orthopedic Surgery
Over the last months, the Rizzoli Orthopedic Institute in Bologna, Italy, has drained orthopedic urgencies from all other hospitals in the urban and suburban area.
- Conditions
- Coronavirus Infection, Orthopedic Disorder, Bone Fracture, Bone Metastases
- Trial name
- COVID19&SURG (NCT05881343)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Ortopedico Rizzoli
SARS CoV 2 Infection
Impact of the Postponement of Surgery on Postoperative Morbidity After Sars-cov-2 Infection
The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification in June 2021of previous recommendations concerning the postponing scheduled surgery suggesting local adaptations of this delay if epidemic…
- Trial name
- DROMIS-22 (NCT05336110)
- Testing
- Postponing surgery
- Where
- 40 sites in France
- Volunteers
- 5,189 people
- Sponsor
- Société Française d'Anesthésie et de Réanimation
COVID-19, SARS-CoV 2
Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global pandemic and is associated with significant morbidity and mortality.
- Trial name
- NCT04413955
- Testing
- Seraph®-100 Microbind® Affinity Blood Filter
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
SARS CoV 2 Infection
Recovering From COVID-19
Following the success of pilot data trialling a virtual community-based remote monitoring model, using Bluetooth enabled pulse oximeters, which demonstrated a saving of 300 bed spaces over a three week period,9 a nationwide…
- Trial name
- OVER-COVID (NCT05302960)
- Testing
- Fitbit
- Sponsor
- Imperial College London
SARS-CoV 2
Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19
Covid-19 infection is due to SARS-CoV-2 member of the Coronavirus family represented by SARS- and MERS-CoVwith neuronal tropism capacity for the brainstem and thalami.
- Trial name
- DEXDO-COVID (NCT04413864)
- Testing
- Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.
Covid-19, SARS-CoV 2
COVID-19 Biorepository
Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.
- Conditions
- Covid-19, SARS-CoV 2, Coronavirus, COVID
- Trial name
- NCT04568148
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- University of Kansas Medical Center
Healthcare Workers, COVID-19
TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)
A randomized parallel double-blinded placebo-controlled clinical trial to evaluate the effect of Emtricitabine/Tenofovir alafenamide (FTC/TAF) compared with placebo on the risk of developing SARS-CoV-2 disease (COVID-19) in…
- Conditions
- Healthcare Workers, COVID-19, SARS-CoV 2
- Trial name
- NCT04405271
- Testing
- Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet
- Where
- Argentina
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome
Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome, Type 2 Diabetes
- Trial name
- DMMETCOV19 (NCT04626089)
- Testing
- metformin glycinate
- Where
- Mexico
- Sponsor
- Laboratorios Silanes S.A. de C.V.
SARS-CoV 2 Infection, Covid19
Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain
Coronavirus disease 2019 (COVID-19) is potentially a deadly disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that targets the lung mainly, resulting in respiratory tract infections in humans.
- Trial name
- NCT04993560
- Testing
- BBIBP-CorV, BNT162b2
- Where
- Bahrain
- Volunteers
- 305 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
COVID, Coronavirus Infection
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
Antioxidants, and particularly polyphenols, have shown protection in respiratory pathologies, which is related to the decrease in the severity of the clinical picture and suppression of inflammation.
- Conditions
- COVID, Coronavirus Infection, SARS-CoV 2, COVID19
- Trial name
- NCT04410510
- Testing
- P2Et (Caesalpinia spinosa extract)
- Where
- Colombia
- Volunteers
- 100 people
- Sponsor
- Hospital Universitario San Ignacio
Upper Respiratory Infection
BD Veritor™ At-Home and BD Veritor™ Professional
The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection…
- Trial name
- NCT05352581
- Testing
- BD Veritor At-Home, BD Veritor Professional
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 1,146 people
- Sponsor
- Becton, Dickinson and Company
COVID, SARS-CoV 2
Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer
The unexpected onset of SARS-COV2 infection modified our practices, especially in routine medicine. In order to reverse the epidemic curve of severe cases and slow the spread of the infection, confinement was generalized in…
- Conditions
- COVID, SARS-CoV 2, Lung Cancer
- Trial name
- CBP-COVID (NCT04366219)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Centre Hospitalier le Mans
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID, COVID 19
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
The aim is to develop a wearable-based ICU (intensive care unit) prediction algorithm for inpatients contracted with SARS-CoV-2. Inpatients with suspicion of COVID-19 or with confirmed SARS-CoV-2 infection will be included.
- Conditions
- COVID, COVID 19, SARS-CoV 2
- Trial name
- WAVE (NCT04357834)
- Testing
- Equipment with smartwatch throughout hospital stay on the general ward
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Covid-19
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
The study is designed as a randomized, controlled, multi-center open-label trial to compare standard-of-care (SOC) treatment with SOC + anakinra or SOC + tocilizumab treatment in hospitalized adult subjects who are diagnosed with…
- Trial name
- NCT04412291
- Testing
- Anakinra Prefilled Syringe, Tocilizumab Prefilled Syringe, Standard-of-care treatment
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska University Hospital
COVID-19, Infectious Disease
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
This is a first in human clinical study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RQ-01. Adult patients who have tested positive for SARS-CoV-2 virus, have mild symptom(s) of COVID-19 disease…
- Conditions
- COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
- Trial name
- NCT06063330
- Testing
- RQ-001
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Red Queen Therapeutics, Inc.
SARS-CoV 2
Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections
Observational cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients and two control groups: one with influenza pneumonia and the other with no viral…
- Trial name
- COVAPID (NCT04359693)
- Where
- France
- Volunteers
- 1,576 people
- Sponsor
- University Hospital, Lille